CUMBERLAND PHARMACEUTICALS, INC.
- NASHVILLE, TN 37203-7003
- cumberlandpharma.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
CUMBERLAND PHARMACEUTICALS, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About CUMBERLAND PHARMACEUTICALS, INC.
- Headquarters
- NASHVILLE, TN 37203-7003
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIM2ZXA6LYJ3S5
- CAGE3VFM4
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 10 awards
- Total awarded
- $4,643,105
- By phase
- STTR Phase I: 6
- SBIR Phase II: 2
- SBIR Phase I: 1
- STTR Phase II: 1
- By agency
- Department of Health and Human Services: 10
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2018: 1
- 2016: 1
- 2014: 1
- 2012: 1
- 2009: 2
- 2005: 2
- 2004: 2
Awards (most recent first)
Targeting DNA damage response pathways for the treatment of advanced lung cancer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $1,994,205
Sep 11, 2018 – Aug 31, 2020
Solicitation PA17-302 (2017) · Topic 102
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,999
Sep 1, 2016 – Aug 31, 2018
Solicitation PA15-270 (2015) · Topic 300
Targeting DNA damage response pathways for the treatment of advanced lung cancer
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $224,910
Solicitation PA13-235 (2014) · Topic NIEHS · Research partner: VANDERBILT UNIVERSITY
Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $246,084
Solicitation PA11-097 (2012) · Topic NIA · Research partner: UNIVERSITY OF VIRGINIA
Radioprotection by use of Topical Lithium Formulations
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $121,528
Solicitation PHS2009-2 (2009) · Research partner: VANDERBILT UNIVERSITY
Mannan, A Potential Therapeutic for Asthma
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $111,805
Solicitation PHS2009-2 (2009) · Research partner: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
High Purity Amphotericin B: A Safer Antimycotic in AIDS
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $110,644
Solicitation PHS2005-2 (2005)
High Purity Amphotericin B: A Safer Antimycotic in AIDS
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $110,644
Research partner: UNIVERSITY OF MISSISSIPPI
TGF-beta for Pleurodesis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $749,143
Solicitation PHS2004-2 (2004)
TGF-beta for Pleurodesis
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2004 · $749,143
Research partner: VANDERBILT UNIVERSITY
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325412Pharmaceutical Preparation ManufacturingPrimarySmall business under this code’s size standard
- 325411Title not in the curated listSmall business under this code’s size standard
SAM.gov reports this entity as small under 2 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with CUMBERLAND PHARMACEUTICALS, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
